ARCT (Arcturus Therapeutics Holdings) Research & Development: $98.85 Mil (TTM As of Mar. 2026)


ARCT Arcturus Therapeutics Holdings Inc ARCT
54 GF Score
Price $6.82
GF Value $4.41
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Arcturus Therapeutics Holdings Research & Development?

Arcturus Therapeutics Holdings ARCT -2.71% 54 Research & Development is $98.85 Mil as of Mar. 2026. GuruFocus rates ARCT with a GF Score™ of 54/100 and a GF Value™ of $4.41 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Arcturus Therapeutics Holdings's Research & Development for the three months ended in Mar. 2026 was $21.53 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $98.85 Mil.

Arcturus Therapeutics Holdings  (NAS:ARCT) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Arcturus Therapeutics Holdings Research & Development Related Terms

Arcturus Therapeutics Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Arcturus Therapeutics Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arcturus Therapeutics Holdings Research & Development Chart

Arcturus Therapeutics Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 173.76 147.75 192.13 195.16 112.21

Arcturus Therapeutics Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.89 29.58 23.27 24.48 21.53
ARCT
54GF Score
Arcturus Therapeutics Holdings Inc ARCT
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arcturus Therapeutics Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $98.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $98.85 Mil mean?
Arcturus Therapeutics Holdings (ARCT) has a Research & Development of $98.85 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Arcturus Therapeutics Holdings and its competitors.
Is Arcturus Therapeutics Holdings' Research & Development too high?
Arcturus Therapeutics Holdings' current Research & Development is $98.85 Mil. Overall, Arcturus Therapeutics Holdings has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcturus Therapeutics Holdings' Research & Development compare to YDES and RNAC?
Arcturus Therapeutics Holdings' Research & Development of $98.85 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Arcturus Therapeutics Holdings and its competitors. Arcturus Therapeutics Holdings's current Research & Development is $98.85 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcturus Therapeutics Holdings stock overvalued right now?
Based on GuruFocus' analysis, Arcturus Therapeutics Holdings (ARCT) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.41, compared to a current price of $6.82 — trading 54.5% above its estimated fair value. The current Research & Development is $98.85 Mil. Arcturus Therapeutics Holdings' overall GF Score™ is 54/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Arcturus Therapeutics Holdings (ARCT), the current Research & Development is $98.85 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcturus Therapeutics Holdings (ARCT) Overvalued in 2026?

Based on GuruFocus' analysis, Arcturus Therapeutics Holdings stock appears to be overvalued. The current stock price of $6.82 is trading 54.5% above its estimated GF Value™ of $4.41. GuruFocus considers Arcturus Therapeutics Holdings to be Significantly Overvalued.

Key valuation signals for ARCT:

  • Research & Development: $98.85 Mil
  • GF Value™: $4.41 vs. price of $6.82 (54.5% above fair value)
  • GF Score™: 54/100 with 4 warning signs

No single metric tells the full story. See the ARCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcturus Therapeutics Holdings Business Description

Address 10285 Science Center Drive, San Diego, CA, USA, 92121
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
54GF Score

Get the complete analysis for ARCT

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.82
Price
$4.41
GF Value